Batelapine

Drug Profile

Batelapine

Alternative Names: Batelapine maleate; Batelapinum; CGS 13429; CGS 13429A

Latest Information Update: 13 Mar 2001

Price : $50

At a glance

  • Originator Novartis
  • Class Antipsychotics; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Psychotic disorders

Most Recent Events

  • 13 Mar 2001 Discontinued-Preclinical for Psychotic disorders (Unknown route)
  • 06 Oct 1998 No-Development-Reported for Psychotic disorders (Unknown route)
  • 16 Jan 1997 Preclinical development for Psychotic disorders (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top